

Curriculum Vitae

Name:

Anyssa Serna

GENERAL INFORMATION

Office Address:

DHR Health
Institute for Research and Development
5323 S. McColl Rd.
Edinburg TX, 78539

Phone Number:

(956) 362-2384

Fax Number:

(956) 362-2383

Email:

an.serna@dhr-rgv.com

Current Employment:

DHR Health – Institute for Research and Development
5323 S. McColl Rd. Edinburg TX, 78539

Education:

South Texas College
McAllen, Texas

Bachelors in Applied Technology – Medical and Health Service Management – December 14, 2019

Associates of Arts Business Administration – December 16, 2017

McAllen Memorial High School
McAllen, Texas
High School Diploma – May 2013

Employee Experience:

Valley Retina Institute, P.A.- McAllen, Texas; Harlingen, Texas; Weslaco, Texas

Clinical Research Coordinator- Feb 2021 – Dec 2022

Duties & Responsibilities:

Recruits, instructs and coordinates research subjects as appropriate to specific study objectives; coordinates the required clinical research project's specific objective. Maintain required documents of study activities including regulatory forms, IRB forms, case reports forms and drug dispensing logs. Engaged in the carrying out of research/clinical protocol, as appropriate to the position, may perform aspects of research protocol, as required, in accordance with specified program objectives. Prepares and ships lab specimens; as well as responsible for data entry and ensuring all study procedures are performed, as per protocol.

Billing assistant, internship - Valley Retina Institute, McAllen, Tx

Position: Intern - August 2019 – November 2019

Duties & Responsibilities:

Responsible for organizing doctors schedules and ensuring that they all have the number of patients capped per day. Ensuring that the doctors are not overbooked. In charge of verifying patient insurance to ensure that the treatment needed is covered by their insurance. Responsible for creating SOP for billing departments.

Customer Service Supervisor - Ticketmaster, Pharr, TX

Position: Supervisor - Feb 2013 – Nov 2020

Responsible for the management of 52 representatives to ensure they are meeting company stats. In charge of conducting training and coaching to staff. Responsible for monitoring and reporting company statistics. Managed team attendance, escalations, and company wide trainings.

Skills/Abilities:

- Bilingual (English & Spanish)
- Injections
- EKG
- Organization
- Reliability
- Detail Oriented
- Integrity
- Teamwork
- Communication
- Front Office/Receptionist
- Time Management
- Certified in Microsoft Office
- Height Measurements and Conversions
- Weight Measurements and Conversions
- Surgery Authorizations
- C-SSRS Screening
- Insurance Verification
- IATA, NIH, HIPPA, GCP Certified
- Ophthalmic Lasers
- Slit lamp examinations
- Temperature Recording (Medications, Ambient, Freezer and Refrigerator)
- Blood Pressure and Pulse Measurements
- Pulse Oximetry Measurements
- Post Operative Care
- Pre-Op Preparations
- Clinical.ly Suite eReg
- Consenting patients

Clinical Research Experience:

- ❖ **Role:** Clinical Research Coordinator **ANN-004:** Dose ascending safety, tolerability, and proof of concept double masked, placebo controlled, randomized study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion
- ❖ **Role:** Clinical Research Coordinator **GR42691:** A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with neovascular age-related macular degeneration (AVONELLE-X)
- ❖ **Role:** Clinical Research Coordinator (Primary) **GR43828:** A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone And Co-Administered with Aflibercept in Patients with Diabetic Macular Edema.
- ❖ **Role:** Clinical Research Coordinator **ADV-022-11:** A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone And Co-Administered with Aflibercept in Patients with Diabetic Macular Edema.
- ❖ **Role:** Clinical Research Coordinator **20739:** A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy
- ❖ **Role:** Clinical Research Coordinator (Primary) **4D-150-C001 GENE THERAPY 4D-150** (adeno-associated virus [AAV] capsid variant [4D-R100] carrying codon-optimized sequence encoding aflibercept protein that binds VEGF-A, VEGF-B, and PlGF [coAFLB] and miRNA targeting VEGF-C)
- ❖ **Role:** Clinical Research Coordinator **GR40306** A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
- ❖ **Role:** Clinical Research Coordinator **010906IN DE -109 LUMINA:** A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.
- ❖ **Role:** Clinical Research Coordinator **AG-920-CS303:** A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaïne Sterile Topical Ophthalmic Solution
- ❖ **Role:** Clinical Research Coordinator **AG-920-CS304:** A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaïne Sterile Topical Ophthalmic Solution (AG-920) in a Pediatric Population
- ❖ **Role:** Clinical Research Coordinator **P2-73305-001:** A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients with Diabetic Macular Edema
- ❖ **Role:** Clinical Research Coordinator **7317-CL-0010:** A Long-term Safety Study of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
- ❖ **Role:** Clinical Research Coordinator (Primary) **OTT166-201:** A Phase 2 Randomized, Double-Masked, Vehicle Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
- ❖ **Role:** Clinical Research Coordinator **END-AU-CS101/201:** Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects with Retinitis Pigmentosa
- ❖ **Role:** Clinical Research Coordinator (Primary) **UBX1325-03:** A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration (ENVISION)
- ❖ **Role:** Clinical Research Coordinator (Primary) **BP43445:** A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone And Co-Administered with Aflibercept in Patients with Diabetic Macular Edema.
- ❖ **Role:** Clinical Research Coordinator (Primary) **EYP-1901-204:** A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
- ❖ **Role:** Clinical Research Coordinator (Primary) **1451-0001** A First in Human trial to study safety and tolerability of single rising intravitreal doses (oPen label, non-randomized, uncontrolled) and in Addition the early biological

Response of multiple intravitreal doses (double-masked, Randomized, sham-controlled) of BI 765128 in panretinal photocoagulation (PRP) treated diabetic retinopathy (DR) patients with diabetic macular ischemia (DMI) – the PARTRIDGE Study

- ❖ **Role:** Clinical Research Coordinator (Primary) **OPL-0401-201** Phase 2 study to evaluate the safety and efficacy of OPL-0401 in patients with non-proliferative diabetic retinopathy
- ❖ **Role:** Clinical Research Coordinator **NTXMCO-004** A Phase 2, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Stargardt Disease [STARLIGHT]
- ❖ **Role:** Clinical Research Coordinator **NTXMCO-002** A Phase 2b Randomized, Double-Masked, Sham-Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Advanced Retinitis Pigmentosa [RESTORE]
- ❖ **Role:** Clinical Research Coordinator **UBX1325-02** A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
- ❖ **Role:** Clinical Research Coordinator **HORNBILL** A First-in Human trial to study safety and tolerability of single rising intravitreal doses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitreal dosing (single-masked, randomized, sham-controlled) of BI 764524 in panretinal photocoagulation (PRP) treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI)
- ❖ **Role:** Clinical Research Coordinator A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME)
- ❖ **Role:** Clinical Research Coordinator A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration A Phase 3, Multicentre, Double-masked, Randomised
- ❖ **Role:** Clinical Research Coordinator (Primary) Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
- ❖ **Role:** Clinical Research Coordinator - A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
- ❖ **Role:** Clinical Research Coordinator - A DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF ORAL AKST4290 IN PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE DIABETIC RETINOPATHY (CAPRI)
- **Role:** Clinical Research Coordinator - A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AVONELLE-X)
- **Role:** Clinical Research Coordinator (Primary) – **Gale** - A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN SUBJECTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
- ❖ **Role:** Clinical Research Coordinator (Primary) A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATOR CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULAR EDEMA
- ❖ **Role:** Clinical Research Coordinator - LONG-TERM EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTIONS FOR THE TREATMENT OF DIABETIC RETINOPATHY FOR SUBJECTS WHO COMPLETED THE 2-YEAR PANORAMA TRIAL (VOYAGE)

- ❖ **Role: Clinical Research Coordinator** - A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular oedema (DME)
- ❖ **Role: Clinical Research Coordinator** - Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 after 28 Day Repeat Oral Administration to Adults with Diabetic Macular Edema
- ❖ **Role: Clinical Research Coordinator (Primary)**- A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA
- ❖ **Role: Clinical Research Coordinator** - A Phase 2/3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
- ❖ **Role: Clinical Research Coordinator** - Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy or Mild Proliferative Diabetic Retinopathy